Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries

Abstract

A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (1). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.

1 . A method of regenerating myocytes or myocardia in the heart of a mammalian subject suffering an injured heart muscle, comprising a step of administering an effective amount of a compound with a backbone structure showing in formula (I) or a functional derivative of said compound: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , wherein said compound is said backbone structure itself without any substitution. 
     
     
         3 . The method of  claim 1 , wherein said compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         4 . The method of  claim 3 , wherein said compound is: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The method of  claim 4 , wherein said injured heart muscle is caused by an ischemic event. 
     
     
         6 . The method of  claim 5 , wherein said ischemic event is myocardial infarction. 
     
     
         7 . The method of  claim 1 , wherein said myocytes or myocardia are regenerated in a process comprising one or more steps of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order. 
     
     
         8 . The method of  claim 7 , wherein said myogenic precursor cells are mesenchymal stem cells coming from bone marrow through blood circulation. 
     
     
         9 . The method of  claim 1 , further comprising the steps of: (a) obtaining a plurality of stem cells; (b) contacting said stem cells with said compound or said functional derivative for a period of time; and (c) transplanting said cells into an infarcted or damaged heart tissue of said mammalian subject. 
     
     
         10 . The method of  claim 1 , further comprising the steps of: (a) formulating said compound or said functional derivative into a dosage form and (b) systematically administering said compound or said functional derivative in said dosage form to said mammalian subject. 
     
     
         11 . The method of  claim 10 , wherein said dosage form is selected from the group consisting of tablet, capsule, injection solution, syrup, suspension and powder. 
     
     
         12 . The method of  claim 1 , further comprising the steps of: (a) culturing a plurality of MSCs or endothelial cells in a culture medium containing said compound or said functional derivative for a period of time; (b) collecting said culture medium, containing secretary proteins from said MSCs or endothelial cells; and (c) administering or delivering said medium to heart tissues in a infarct area. 
     
     
         13 . The method of  claim 1 , wherein at least 95% by weight of said composition is identified compounds. 
     
     
         14 . The method of  claim 1 , further comprising adding a piece of information on usefulness of said compound, wherein said information indicates that said compound is beneficial to a human suffering or having suffered a heart disease. 
     
     
         15 . The method of  claim 1 , further comprising adding a piece of information on usefulness of said compound, wherein said information indicates that said compound is beneficial to regenerate myocytes or myocardia in the heart of said mammalian subject. 
     
     
         16 . A pharmaceutical composition comprising a substantially purified compound of the following formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient. 
     
     
         17 . A pharmaceutical composition comprising a substantially purified compound of the following formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient.